RU2127099C1 - Ocular drops "neokeratonik" - Google Patents

Abstract

FIELD: ophthalmology. SUBSTANCE: invention is distinguished by that known ocular drops containing, wt %: sodium succinate hexahydrate, 1.91; sodium citrate 5.5-hydrate, 0,40; sodium chloride, 0.31; sorbitol, 0.80; L-glutamic acid, 0.015; benzalkonium chloride, 0.014; riboflavin mononucleotide phosphate, 0.02; and water, the balance, additionally contain glucose, 0.30. In one of the versions of invention, ocular drops additionally contain taurine in quantity of 0.4 g per 100 ml. EFFECT: extended choice of therapeutic means. 2 cl, 3 ex

Description

 The invention relates to medicine, namely to ophthalmology, and can be used for pharmacological protection of the transplant after keratoplasty and long-term treatment of epithelial-endothelial dystrophy of the cornea.

 Known eye drops "Keratonic" containing sodium succinate, sodium citrate, sorbitol, sodium chloride, benzalkonium chloride, glutamic acid, riboflavin mononucleotide phosphate and distilled water (Patent N 2056821).

 The disadvantage of these drops is the slow flow of energy reactions in the cells of the cornea.

 The objective of the invention is the development of multicomponent eye drops to improve energy metabolism in the cells of the anterior, posterior corneal epithelium and keratoblasts in any process that disrupts this metabolism.

 The technical result is the acceleration of energy reactions in the cycle of tricarboxylic acids in the cells of the anterior and posterior corneal epithelium and keratoblasts.

The technical result is achieved by the fact that the known eye drops contain sodium succinate hexahydrate, sodium citrate 5.5-aqueous, sodium chloride, sorbitol, glutamic acid, benzalkonium chloride, riboflavin mononucleotide phosphate and distilled water, according to the invention they additionally contain glucose in the following ratio of components, wt.%
Sodium succinate, six-water - 1.91
Sodium Citrate 5.5-Aq - 0.40
Sorbitol - 0.80
Sodium chloride - 0.31
L-glutamic acid - 0.015
Riboflavin Mononucleotide Phosphate - 0.02
Benzalkonium chloride - 0.015
Glucose - 0.30
Distilled Water for Injection - Other
One embodiment of the invention is one in which the eye drops further comprise taufon (taurine) in an amount of 0.4 g / 100 ml.

Eye drops are prepared as follows: in eight chemically pure sterile cups, make separately in the proposed doses: sodium succinate, six-water, sodium citrate 5.5-aqueous, sorbitol, sodium chloride, L-glutamic acid, riboflavin mononucleotide phosphate, benzalkonium chloride, glucose; they are diluted with a small amount of sterile distilled water for injection (5-7 ml) until completely dissolved. Moreover, L-glutamic acid is dissolved in water at a temperature of 70 ^o C, followed by cooling to room temperature, and riboflavin mononucleotide phosphate in a darkened room with scattered light. In the case of taurine, it is also dissolved in a separate glass under normal conditions. Then all dissolved components are successively poured into a sterile, chemically pure volumetric flask. The volume of the flask is adjusted with distilled water to 100 ml. Then the first sterile filtration of the solution is performed (through 0.22 μm Millipor filters) in a sterile box in a laminar cabinet, subject to all the rules for the release of thermolabile preparations for parenteral use. The solution is bottled in sterile vials (drunk flasks) of 10 ml each by secondary filtration through a millipore nozzle with a pore diameter of 0.22 μm. The bottles are corked with a silicone stopper and an aluminum cap for hard break-in. Labeled and stored in accordance with the requirements of the State Pharmacopoeia X-XI.

 Example 1. Patient K., 42 years old. The diagnosis is a condition after end-to-end subtotal keratoplasty of the left eye (3 days after surgery). Clinically expressed corneal syndrome, edema of all layers of the native corneal transplant.

 The patient was prescribed Neokeratonic 6 times a day, 2 drops in the operated eye (against the background of immunosuppressive therapy with dexamethasone and sandimmun).

 By the end of 1 day from the beginning of the instillation of the drug, a moderate severity of the corneal syndrome, significant clarification of the cornea was achieved, and after 3 days the edema of all layers of the cornea was completely eliminated. The eye is calm. The patient was discharged for outpatient treatment on the 8th day. As a supporting metabolic therapy, the drug was recommended for 3 months 4 times a day, 2 drops each. At the control examination after 3 months, the eye is calm, the corneal transplant is completely transparent.

 Example 2. Patient Sh., 46 years old. The diagnosis is secondary epithelial-endothelial dystrophy of the cornea, artifact of the right eye. Clinically, the anterior epithelium is swollen like a “foggy glass”, the stroma is moderately swollen and thickened over the entire area of the cornea, the endothelial layer in the optical section is difficult to see.

 The patient was prescribed the proposed drug "Neokeratonic" in the form of instillations 4-6 times a day, 2 drops for 2-3 days (until a pronounced clinical effect is obtained). After 3 days, the desired effect was achieved, after which the patient continued to receive “Neokeratonic” in a maintenance dose of 2 drops 2 times a day for 6-12 months. At the indicated observation period, relapse of dystrophy was not observed.

 Example 3. Patient B., 34 years. The diagnosis is incomplete post-traumatic cataract of the left eye. Phacoemulsification of a cloudy lens with a large volume of washing fluid was performed, after which there was a pronounced clouding of the endothelial layer of the cornea and lower stroma layers by the end of the operation.

 Immediately after surgery, the patient was prescribed the drug "Neokeratonic" in the form of instillations of 2 drops every hour. By the end of the 12th hour after the operation, the cornea looked completely transparent and the patient had objective vision. From the next day, the drug was instilled 2 times a day, 2 drops for 5 days to maintain the pump function of the endothelium and consolidate the clinical effect.

 Thus, the use of Neokeratonic eye drops can effectively stop various forms of keratopathy associated with inadequate endothelial function of the cornea.

 Long-term use of the drug "Neokeratonic" in our observations did not reveal its side effects and cases of toxic-allergic nature.

Claims (1)

1. Eye drops, including sodium succinate, six-water, sodium citrate, 5.5-aqueous, sodium chloride, sorbitol, L-glutamic acid, riboflavin mononucleotide phosphate, benzalkonium chloride, distilled water for injection, characterized in that they additionally contain glucose in the following ratio components, wt.%:
Sodium succinate, six-water - 1.91
Sodium Citrate 5.5-Aq - 0.40
Sorbitol - 0.80
Sodium chloride - 0.31
L-glutamic acid - 0.015
Riboflavin Mononucleotide Phosphate - 0.02
Benzalkonium chloride - 0.015
Glucose - 0.30
Distilled Water for Injection - Other
2. Eye drops according to claim 1, characterized in that they additionally contain taufon (taurine) in an amount of 0.4 g / 100 ml.